TNFRSF25 and colitis: The strategies we used for blocking loss of ILC3s using α-GM-CSF, α-p19, α-p40, or DR3-Fc in this study may also simultaneously ameliorate colitis by limiting the pathogenicity of ILC3s or other mechanisms26,64.